Part­ner and fund­ing

What is Tar­get Late AMD?

Our two first pro­jects were de­signed to treat rather early stages of AMD be­fore cell loss has been oc­curred. This third pro­ject aimed at treat­ing ad­vanced stages of AMD.

Learn more

Our goal with Tar­get Late AMD

Goals

The gene the­ra­py ap­proach based on Tar­get AMD 1.0, con­sist in the trans­plant­a­tion of a pa­tient’s own iris pig­ment ep­ithe­lial (IPE) cells ge­net­ic­ally mod­i­fied to over­ex­press thera­peut­ic genes aim­ing at re­cov­er­ing a healthy reti­nal en­vir­on­ment, stop­ping ves­sel growth (in wet AMD), or re­du­cing in­flam­ma­tion and oxi­dative stress (in dry AMD).

Learn more

What is Tar­get Late AMD?

Pro­ject status/Results

Tar­get Late AMD star­ted in Novem­ber 2022. The cur­rent pro­ject will be com­pleted in April 2024 and fo­cus on the es­tab­lish­ment of the pro­duc­tion of the cell product, i.e., reti­nal pig­ment ep­ithe­lial (RPE) cells de­rived from auto­log­ous in­duced pluri­po­tent stem cells (iPSC) and ge­net­ic­ally mod­i­fied (trans­fec­ted) to pro­duce thera­peut­ic factors (PEDF and GM-CSF) aim­ing at re­cov­er­ing a healthy reti­nal en­vir­on­ment.

Learn more